Literature DB >> 8125214

Lack of peroxisome proliferation in marmoset liver following treatment with ciprofibrate for 3 years.

M J Graham1, S A Wilson, M A Winham, A J Spencer, J A Rees, S L Old, F W Bonner.   

Abstract

The effect of treatment of marmosets with ciprofibrate for 3 years on activities of hepatic enzymes, hepatic histomorphology, and ultrastructure were investigated. Male and female marmosets were dosed with ciprofibrate (2, 10, and 20 mg/kg) by oral gavage once daily for 3 years. No effect on liver weight (adjusted for body weight) or liver morphology was observed. The activities of catalase, glutathione peroxidase, alpha-glycerophosphate dehydrogenase, benzphetamine N-demethylase, and ethoxyresorufin O-deethylase were unaffected by treatment with ciprofibrate. Activity of glutathione transferase was increased in the low dosage group but unaffected in the mid and high dosage groups. Modest increases in activities of peroxisomal beta-oxidation (2.5-fold, maximal), carnitine acetyl transferase (1.7-fold, maximal), and carnitine palmitoyl transferase (2-fold, maximal) were observed. Cytochemical staining and quantitative image analysis failed to indicate any effect on peroxisomal number, size, or volume density. Similarly, there was no increase in lipofuscin deposition. This study provides data on the effects of a potent peroxisome proliferator on primate liver following a dosing period much greater than that used in previously published studies and is further evidence that the marmoset is relatively insensitive to the well-documented effects that ciprofibrate and other peroxisome proliferators have on rat liver.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8125214     DOI: 10.1006/faat.1994.1008

Source DB:  PubMed          Journal:  Fundam Appl Toxicol        ISSN: 0272-0590


  5 in total

1.  Single and chronic administration of ciprofibrate or of ciprofibrate-glycinate in male Fischer 344 rats: comparison of the effects on morphological and biochemical parameters in liver and blood.

Authors:  Amelie Lupp; Elke Karge; Manfred Danz; Thomas Deufel; Herbert Oelschläger; Wolfgang Klinger
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2005 Jul-Sep       Impact factor: 2.441

Review 2.  Peroxisome proliferator-activated receptor-alpha and liver cancer: where do we stand?

Authors:  Jeffrey M Peters; Connie Cheung; Frank J Gonzalez
Journal:  J Mol Med (Berl)       Date:  2005-06-23       Impact factor: 4.599

3.  The Common Marmoset-Biomedical Research Animal Model Applications and Common Spontaneous Diseases.

Authors:  Hyo-Jeong Han; Sarah J Powers; Kathleen L Gabrielson
Journal:  Toxicol Pathol       Date:  2022-05-10       Impact factor: 1.930

4.  Effect of a Large Dose of Di (2-ethylhexyl) phthalate (DEHP) on Hepatic Peroxisome in Cynomolgus Monkeys (Macaca Fascicularis).

Authors:  Shigeru Satake; Chika Nakamura; Yoshiyuki Minamide; Shinobu Kudo; Hiroshi Maeda; Yutaka Chihaya; Yasuhiro Kamimura; Hiroaki Miyajima; Jun Sasaki; Masanobu Goryo; Kosuke Okada
Journal:  J Toxicol Pathol       Date:  2010-06-30       Impact factor: 1.628

5.  Overview of the marmoset as a model in nonclinical development of pharmaceutical products.

Authors:  Antonia Orsi; Daryl Rees; Isabella Andreini; Silvana Venturella; Serena Cinelli; Germano Oberto
Journal:  Regul Toxicol Pharmacol       Date:  2010-12-13       Impact factor: 3.271

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.